ArticlePLOS global public health2026
Improving malaria chemoprevention coverage in pregnancy: Surveying stakeholder preferences for new product profiles and community-delivery approaches across five African countries.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sulfadoxine-pyrimethamine (SP) is the only WHO-recommended option for the intermittent preventive treatment of malaria in pregnancy (IPTp). However, coverage is suboptimal, efficacy is limited in areas of high resistance and SP is contraindicated in the first trimester and women living with HIV receiving cotrimoxazole. This study investigated stakeholder perspectives on next-generation IPTp product characteristics and their potential impact on uptake, adherence and community deployment. Surveys were conducted in five malaria endemic countries, including pregnant women (n = 75), nurses/community health workers (CHWs) (n = 53), clinicians (n = 75) and policymakers (n = 51). Surveys included quantitative elements and open-ended questions to examine stakeholder perceptions of chemoprevention product characteristics influencing uptake, adherence and implementation. Additionally, a discrete choice experiment (DCE) conducted among clinicians and policymakers compared next-generation IPTp oral product profiles against SP. Across stakeholders the most important attribute was safety in all trimesters, followed by short duration of therapy, few tablets per day, food requirements and impact on birthweight was the least influential. Clinicians and policymakers also believed resistance markers to be important. All stakeholder groups indicated that a long-acting injectable with at least three months' coverage would enhance adherence. For oral medication, pregnant women believed being able to take food with treatment was the most important attribute to enhance adherence, while a four-tablet daily dosing would decrease adherence. Clinicians and policymakers felt that delivery by CHWs would increase adherence and expand IPTp uptake in currently unreached women. However, three-quarters of pregnant women preferred ante-natal clinic delivery of a new medicine. The DCE favored products without food restrictions most strongly. This study offers important insights for the development and deployment of next-generation IPTp products. Minimizing food-related restrictions and addressing resistance concerns are key priorities, together with safety and tolerability. Long-acting injectable formulations and hybrid delivery models could play a substantial role in improving adherence and uptake.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.